Updates, milestones, and links shared by Spark Biomedical.
Completed Enrollment of Neonatal Opioid Withdrawal Syndrome clinical study. Targeting Q2 submission to FDA.
Spark completed its first trial for menstrual health where subjects used neurostimulation for 2 hours per day during menstruation. Participants saw a 55% reduction in blood loss, 25% reduction in cycle duration, 50% reduction in cramp pain and significant improvement in mood, anxiety, and quality of life.
CMS issues unique HCPCS Codes for Sparrow Ascent
Second generation wearable neurostimulation platform cleared for opioid withdrawal management. Reducing COGS by 75% over gen 1.
Spark Biomedical just completed a joint venture agreement with Northwell Health and the Feinstein Institute to bring a new novel neuromodulation therapy to market. The new subsidiary, 5 Liters, will take over a decade of preclinical work lead by Kevin Tracey and his team at the Feinstein institute using neurostimulation of the Vagus nerve to activate platelets in order to reduce blood loss and stop bleeding. This novel approach to blood management has applications on the battlefield, in the OR, emergency room, and around the world where expensive hemostatic agents aren't available. 5 Liters will translate the preclinical work to humans and bring this novel, potentially life saving blood management solution to market.
In the last week, Spark was awarded 1) Edison Awards - Bronze for innovation in Healthcare 2) 3 Platinum, 4 Gold, and 1 honorable mention Hermes Awards for creative design 3) Fast Company Most Innovative Company - Honorable Mention.